<DOC>
	<DOCNO>NCT00719524</DOCNO>
	<brief_summary>The purpose study determine recommend dose combination AVE8062 platinum salt ( cisplatin carboplatin ) taxanes ( docetaxel paclitaxel ) patient advance solid tumor platinum-taxane doublet constitutes mainstay care .</brief_summary>
	<brief_title>AVE8062 Combination With Platinum-taxane Doublet Advanced Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Taxane</mesh_term>
	<criteria>Advanced neoplastic disease ( i.e . metastatic locally advanced disease ) platinumtaxane doublet regimens approve constitutes mainstay care non small cell lung cancer , epithelial ovary cancer , gastric cancer , transitional cell bladder cancer head neck cancer . Eastern cooperative oncology group ( ECOG ) performance status 0 1 . Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , radiotherapy ( exclude radiotherapy palliative intent nontarget lesion ) , target therapy , gene therapy , patient plan receive treatment study . Absence histologically cytologically proven cancer first diagnosis . Negative serum/urinary pregnancy test Washout period 3 week prior antitumor therapy investigational treatment The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Antineoplastic Combined Chemotherapy Protocol</keyword>
</DOC>